Debiopharm, ThinkingNodeLife.ai join forces to advance AI-driven cancer drug development
Debiopharm, an independent biopharmaceutical company based in Switzerland, has forged a collaborative partnership with USA's ThinkingNodeLife.ai (TNL), a pioneer in AI Digital Cells Lab, to ... Read More
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) ... Read More
FDA approves Ryzneuta by Evive Biotech for reducing febrile neutropenia in cancer patients
Evive Biotech, a global biopharmaceutical company and a subsidiary of Yifan Pharmaceutical Co. Ltd., along with New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo ... Read More
ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug ... Read More
Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises ... Read More
Venus Remedies expands cancer drug portfolio in South Eastern Europe
In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs ... Read More
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More
ENB Therapeutics completes Phase 1 trial enrollment for ENB-003
ENB Therapeutics, a biotechnology firm working on therapeutics targeting the endothelin B receptor (ETBR), announced the completion of its international Phase 1 ENBOLDEN-101 trial enrollment. ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More
Your diet soda could be deadly: What international agencies say about Aspartame
the International Agency for Research on Cancer (IARC) and the Joint Expert Committee on Food Additives (JECFA), of the World Health Organization (WHO) and the ... Read More